Physician profile
Tara Beth Coyle
NPI 1720670342
$7,122.52
in general payments reported to CMS, 2019-2025
39 companies · $1,766 in 2025
The $1,766 reported for 2025 was more than what 94% of Primary Care providers received nationally (typical 2025 total: $170).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $255 · 2022: $946 · 2023: $2,178 · 2024: $1,977 · 2025: $1,766.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,887 · Education: $34.37.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,887.11 |
| Education | $34.37 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,465.53 | 2021-2025 | |
| Novo Nordisk INC | $831.30 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Amgen INC. | $571.30 | 2021-2025 | Repatha, Evenity, Otezla |
| Pfizer INC. | $516.81 | 2023-2025 | |
| Lilly USA, LLC | $492.63 | 2022-2025 | Mounjaro, Jardiance, Zepbound |
| Bayer Healthcare Pharmaceuticals INC. | $411.17 | 2022-2025 | |
| Bausch Health US, LLC | $391.73 | 2023-2025 | Aplenzin, Wellbutrin |
| Astrazeneca Pharmaceuticals LP | $231.95 | 2022-2025 | Farxiga, Airsupra, Breztri |
| Exact Sciences Corporation | $228.43 | 2023-2025 | Cologuard Collection Kit |
| Glaxosmithkline, LLC. | $215.00 | 2021-2024 | Arexvy, Shingrix, Trelegy Ellipta |
| Novartis Pharmaceuticals Corporation | $210.42 | 2023-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $155.77 | 2022-2025 | Trintellix |
| Esperion Therapeutics, INC. | $138.65 | 2021-2025 | Nexletol |
| Boehringer Ingelheim Pharmaceuticals, INC. | $135.80 | 2023-2024 | Jardiance, Spiriva Respimat, Stiolto Respimat |
| Mylan Specialty L.P. | $117.60 | 2023-2024 | Yupelri |
Show all 39 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tara Coyle listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.